Skip to main content

Table 1 description of the patient characteristics, treatments and other variables

From: Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data

Characteristic

All women (N = 598)

Women who did not have recurrence (N = 477)

Women who had recurrence (N = 121)

P value

Age, Median (IQR), year

40 (36–53)

40 (36–54)

40 (36–50)

0.272

Study follow-up, Median (IQR), year

4 (3–5)

4 (2–5)

4 (3–5)

0.091

Year of Diagnosis

   

0.33

 2007–2009

259 (43.3)

208 (43.6)

51 (42.1)

 

 2010–2012

192 (32.1)

147 (30.8)

45 (37.2)

 2013–2015

147 (24.6)

122 (25.6)

25 (20.8)

Stage

   

<.0001

 0

2 (0.3)

2 (0.4)

0 (0)

 

 I

93 (15.6)

84 (17.6)

9 (7.4)

 II

311 (52.0)

270 (56.6)

41 (33.9)

 III

192 (32.1)

121 (25.4)

71 (58.7)

Tumor grade

   

0.012

 1

32 (5.3)

32 (6.7)

0 (0.0)

 

 2

211 (35.3)

167 (35.0)

44 (36.4)

 3

342 (57.2)

270 (56.6)

72 (59.5)

 Unknown

13 (2.2)

8 (1.7)

5 (4.1)

Histology

   

0.352

 Ductal

538 (90.0)

432 (90.6)

106 (87.6)

 

 Lobular

27 (4.5)

22 (4.6)

5 (4.1)

 Ductal lobular mixed

10 (1.7)

6 (1.3)

4 (3.3)

 Other

23 (3.8)

17 (3.5)

6 (5.0)

ER status

   

0.266

 Positive

439 (73.4)

355 (74.4)

84 (69.4)

 

 Negative

159 (26.6)

123 (25.6)

37 (30.6)

PR status

   

0.216

 Positive

375 (62.7)

305 (63.9)

70 (57.8)

 

 Negative

223 (37.3)

172 (36.1)

51 (42.2)

HER2 status

   

0.028

 Positive

161 (26.9)

138 (28.9)

23 (19.0)

 

 Negative

437 (73.1)

339 (71.1)

98 (81.0)

Surgery

   

0.003

 No surgery

5 (0.8)

4 (0.8)

1 (0.8)

 

 BCS

159 (26.6)

141 (29.6)

18 (14.9)

 Mastectomy

434 (72.6)

332 (69.6)

102 (84.3)

Chemotherapy

   

0.614

 Yes

547 (91.5)

436 (91.4)

111 (91.8)

 

 No

40 (6.7)

31 (6.5)

9 (7.4)

 Unknown

11 (1.8)

10 (2.1)

1 (0.8)

Radiation therapy

   

0.587

 Yes

194 (32.4)

150 (31.5)

44 (36.4)

 

 No

209 (35.0)

169 (35.4)

40 (33.0)

 Unknown

195 (32.6)

158 (33.1)

37 (30.6)

Hormone therapy

   

0.396

 Yes

214 (35.8)

177 (37.1)

37 (30.6)

 

 No

192 (32.1)

149 (31.2)

43 (35.5)

 Unknown

192 (32.1)

151 (31.7)

41 (33.9)

Death

   

<.0001

 Yes

92 (15.4)

13 (2.7)

77 (63.6)

 

 No

506 (84.6)

464 (97.3)

44 (36.4)

Cause of death

   

<.0001

 Death due to breast cancer

76 (12.7)

10 (2.1)

66 (54.5)

 

 Death due to other causes

16 (2.7)

3 (0.6)

11 (9.1)

 Alive

506 (84.6)

464 (97.3)

44 (36.4)

  1. IQR interquartile range, ER estrogen receptor, PR progesterone receptor, HER2 Human Epidermal growth factor Receptor 2